Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 6OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 218Rectal Neoplasms 107Colonic Neoplasms 91Pancreatic Neoplasms 88Stomach Neoplasms 75Neoplasm Metastasis 61Esophageal Neoplasms 40Carcinoma, Hepatocellular 31Lymphoma 24Adenocarcinoma Of Esophagus 24Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Adenocarcinoma 19Leukemia 17Cholangiocarcinoma 15Biliary Tract Neoplasms 15Burkitt Lymphoma 14Gastrointestinal Neoplasms 12Lymphoma, Non-Hodgkin 11Osteosarcoma 9Liver Neoplasms 9Gallbladder Neoplasms 9Esophageal Squamous Cell Carcinoma 9Peritoneal Neoplasms 8Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 7Lymphoma, Large B-Cell, Diffuse 7Bile Duct Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Multiple Myeloma 6

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × Leucovorin × Clear all
NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

Phase 1/2 Terminated
19 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡